-
A Patient-Level Simulation to Bridge Data Gaps in Cost-Effectiveness Modeling of B-VEC for Dystrophic Epidermolysis Bullosa
Sep 9, 2025, 16:22 PM -
Evaluating GenAI vs. Human Screenshot Review Outputs in eCOA Localization: Does AI Hold the Key to Improved Feedback?
Sep 9, 2025, 16:22 PM -
Artificial Intelligence-Powered Literature Reviews (AILRs): Streamlining Joint Clinical Assessment (JCA) Dossier Preparation for the Next Generation of Pharmaceutical Submissions
Sep 9, 2025, 16:22 PM -
Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain
Sep 9, 2025, 16:22 PM -
Pulmonary Nodule (PN)-Related and Lung Cancer-Related Workup Costs Within the Two-Year Period After Diagnosis of a PN in the United States
Sep 9, 2025, 16:22 PM -
A Cost-Effectiveness Analysis of Ustekinumab Against Vedolizumab Among Inflammatory Bowel Disease Patients With Extra-intestinal Manifestations in Egypt
Sep 9, 2025, 16:22 PM -
Value of Patient-Reported Outcomes Data in Food and Drug Administration Labeling of Oncology Drugs to Payers in the United States
Sep 9, 2025, 16:22 PM -
Enterocutaneous Fistula (ECF) and Economic Burden Preliminary Data From a HEOR Model of a Laboratory (LAB) Experiment Plus Potential Cost Avoidance
Sep 9, 2025, 16:22 PM -
Comparative Epidemiological Burden of Osteoarthritis in Eastern Central and Western Europe Based on the Global Burden of Disease Study 2021
Sep 9, 2025, 16:22 PM -
Standardizing Point-of-Care mRNA-Based Gene Therapy Production in Europe: A Cost and Capacity Analysis of the Nanospresso Platform
Sep 9, 2025, 16:22 PM -
Evaluating the Efficacy of Artificial Intelligence Models as Suitable Screening Tools in Systematic Reviews: The Example of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure Treatment
Sep 9, 2025, 16:22 PM -
Oracle Real-World Data: Analysis of the Characteristics and Representativeness of Oracle's Linked EHR-Claims Database
Sep 9, 2025, 16:22 PM -
Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France
Sep 9, 2025, 16:22 PM -
The Value of Investing in Innovative Medicines: A Scalable Approach to Measure the Lifetime Social Impact
Sep 9, 2025, 16:22 PM -
Cross-Country Comparison of Cancer-Related Health Preferences Using the EORTC QLU C10D: Evidence Supporting Standardized Value Sets
Sep 9, 2025, 16:22 PM -
A Comprehensive Review of Health Technology Reassessments for Oncology Drugs in France: Impact on Reimbursement Outcomes 2019-2024
Sep 9, 2025, 16:22 PM -
Effect of Education Given to Nursing Students on Their Palliative Care Knowledge and Attitudes
Sep 9, 2025, 16:22 PM -
The Reliability and Validity of the Greek Version of the Pediatric Quality of Life Inventory™ 30 Duchenne Muscular Dystrophy Module in Children With Duchenne Muscular Dystrophy
Sep 9, 2025, 16:22 PM -
Treatment Patterns of Rare Immunodeficiencies With Special Regard to Antibiotics: A German Claims Data Analysis
Sep 9, 2025, 16:22 PM -
Effective Use of Reconstructed Survival Data for Individual-Level Correlation Assessment in Oncology: A Case Study in Metastatic-Hormone Sensitive Prostate Cancer (mHSPC)
Sep 9, 2025, 16:22 PM
